Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
Clazakizumab
Другие языки:

Clazakizumab

Подписчиков: 0, рейтинг: 0
Clazakizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IL6
Clinical data
Other names ALD518, BMS-945429
Routes of
administration		 infusion
ATC code
  • none
Legal status
Legal status
  • investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6426H9972N1724O2032S42
Molar mass 145239.02 g·mol−1

Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.

See also


Новое сообщение